AXQ Capital LP Takes $454,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

AXQ Capital LP bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,287 shares of the biotechnology company's stock, valued at approximately $454,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics during the third quarter valued at about $33,000. Millstone Evans Group LLC purchased a new stake in United Therapeutics in the fourth quarter worth about $67,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the period. Finally, Jones Financial Companies Lllp lifted its position in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 1.0 %

United Therapeutics stock traded down $3.29 during midday trading on Tuesday, reaching $316.57. The stock had a trading volume of 209,211 shares, compared to its average volume of 446,533. The firm has a market cap of $14.22 billion, a price-to-earnings ratio of 13.90, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The company has a fifty day moving average of $344.24 and a 200 day moving average of $356.84.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the business posted $4.36 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Insiders Place Their Bets

In related news, Director Nilda Mesa sold 255 shares of the firm's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company's stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 80,255 shares of company stock worth $28,995,021 over the last quarter. Company insiders own 11.90% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.